# FDA Extends Casgevy CRISPR Gene Therapy to Children as Young as Age 2 for Sickle Cell Disease

> fda · REPORTED · 2026-07-01

The FDA issued a supplemental approval on July 1, 2026 expanding Casgevy (exagamglogene autotemcel) to patients aged 2 and older with sickle cell disease and transfusion-dependent beta thalassemia, lowering the age threshold from 12 in just 53 days of review under the agency's Commissioner's National Priority Voucher pilot program. This is the broadest CRISPR-based gene therapy label ever granted by the FDA.

- Company: Vertex Pharmaceuticals / CRISPR Therapeutics (Casgevy)
- Sector: biotech
- Primary source: https://healthcarereaders.com/news/healthcare-news-27th-june-to-4th-july-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.